Item 2. Unregistered Sales of Equity Securities
Item 2. Unregistered Sales of Equity Securities and Use of Proceeds
In February 2025, we consummated the acquisition of certain manufacturing assets from C S Bio Co. (the “Seller”) , pursuant to which we issued 292,806 shares of Class A common stock to the Seller representing a portion of the consideration for such transaction, which securities were valued at $12.8 million for accounting purposes. For more detail regarding the transaction, see Note 3 – Acquisitions to the unaudited condensed consolidated financial statements included in Part I, Item 1 of this Quarterly Report on Form 10-Q. We issued the foregoing securities in a transaction not involving an underwriter and not requiring registration under Section 5 of the Securities Act, in reliance on the exemption afforded by Section 4(a)(2) thereof.
There were no repurchases of our Class A common stock under the authorized 2024 Share Repurchase Program during the three months ended March 31, 2025.
Text extracted from the filing as submitted to EDGAR. Formatting, tables and exhibits are simplified for reading; the original document is authoritative for anything you rely on.